The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Mayo Clinic Lymphoma eTumor Board | Transformed follicular lymphoma
This case study discusses the presentation and management of an asymptomatic patient with transformed follicular lymphoma and progressive abdominal lymphadenopathy after initial complete metabolic response to rituximab.
This patient case study has been graciously provided to the Lymphoma Hub by the Mayo Clinic Lymphoma eTumor Board (January 15, 2020). The treatment options discussed in this video represent the opinion of the Mayo Clinic experts based on North American guidelines, drug approvals in the US, or clinical trials.
For more information, expert opinions, and case studies in Lymphoma, please visit www.lymphomahub.com.
Mayo Clinic Lymphoma eTumor Board | Transformed follicular lymphoma